{'fraction_non_alphanumeric': 0.026772793053545588, 'fraction_numerical': 0.023878437047756874, 'mean_word_length': 5.065789473684211, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
MiR-19a overexpression contributes to heart failure through targeting ADRB1.

Beta1-adrenoreceptor (β1-AR) predominantly exists in the heart and β1-AR reduction is closely related to severity of heart failure (HF). In this study, our research focused on the miRNAs that may repress β1-AR directly, and aim to find out new markers and target molecules for HF. We first did Argonaute2 AGO2 knock down experiments and confirmed that endogenous adrenoceptor beta 1 (ADRB1) expression was suppressed by miRNAs. To further identify which miRNA suppress ADRB1 expression directly, we constructed the ADRB1 3'UTR reporter plasmid and selected sixteen candidate miRNAs. Confirmed by dual-luciferase assay and western blot, we found that miR-19a suppressed ADRB1 expression by directly targeting 3'UTR. Further expressions detection the levels of miR-19a, BNP and cAMP in 32 plasma samples of HF patients helped us to construct positive correlations between the expression levels of miR-19a and BNP or cAMP, hints miR-19a may be used as a biomarker in HF patients indicating cardiac function. In conclusion, this study confirmed miR-19a suppressed ADRB1 expression by directly targeting 3'UTR of ADRB1 and found an positive correlation between plasma miR-19a and BNP or cAMP levels in HF patients, which may contributes to fully understand the HF pathogenesis and develops new therapy for HF.